The abstract is read at the publisher; the summary is JClub's.
Dynamic 18F-PI-2620 tau-PET in 129 tauopathy patients predicts β-amyloid positivity with AUC 0.99, enabling simultaneous A/T/N staging from one 60-minute scan.
- Why it matters: Molecular A/T/N classification needs amyloid, tau, and neurodegeneration measures, but overlapping clinical presentations and multi-scan workflows limit streamlined, individualized assessment.
- What they did: Patients underwent 60-minute dynamic 18F-PI-2620 tau-PET; kinetic modeling produced K2a for β-amyloid status, DVR for regional tau burden, and R1 for neurodegeneration, validated against β-amyloid-PET, 18F-FDG-PET, MRI, and CSF biomarkers, then tested in an independent cohort of 97.
- The result: K2a distinguished 3/4-repeat versus 4-repeat tauopathies and predicted β-amyloid positivity with PPV 91.5% and NPV 95.1% (AUC 0.99), remaining robust in validation (AUC 0.98; PPV 87.9%; NPV 95.3%), while DVR and R1 supported individualized three-dimensional A/T/N staging.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.